Editorial
Copyright ©The Author(s) 2025.
World J Hepatol. Mar 27, 2025; 17(3): 105255
Published online Mar 27, 2025. doi: 10.4254/wjh.v17.i3.105255
Figure 1
Figure 1 The interactions between non-alcoholic fatty liver disease and drug use, focusing on three main pathways: Changes in cytochrome P450 enzymes, oxidative stress, and immunological responses. NAFLD: Non-alcoholic fatty liver disease; CYPs: Cytochrome P450 enzymes; ROS: Reactive oxygen species, IL-4: Interleukin-4; IgM: Immunoglobulin M; C3: Complement component 3.